Immunoglobulin A (IgA): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Immunoglobulin A (IgA) is the dominant antibody class on mucosal surfaces—respiratory, gastrointestinal, and genitourinary tracts—and in secretions such as saliva, tears, and breast milk. It exists primarily as a dimer linked by a J chain and secretory component, which protects it from proteolytic degradation. IgA serves as the immune system's frontline defence, neutralising pathogens before they invade deeper tissues. In blood, it circulates mainly as a monomer. Total IgA measurement is essential for diagnosing selective IgA deficiency (the most common primary immunodeficiency), assessing humoral immune competence, and monitoring certain monoclonal gammopathies (IgA myeloma). It is also elevated in a range of inflammatory, infectious, and autoimmune conditions, particularly those involving mucosal surfaces or the liver. IgA does not cross the placenta.

---

2. What does it measure

a. Units of measurement

· Grams per litre (g/L) – most common

· Milligrams per decilitre (mg/dL) – conversion: g/L × 100 = mg/dL

b. Normal Range (age‑dependent; reference intervals vary by laboratory)

· Adults: 0.7 – 4.0 g/L (70 – 400 mg/dL)

· Children:

· Birth – 1 month: 0.0 – 0.1 g/L (virtually absent; mature levels develop over years)

· 1 – 6 months: 0.05 – 0.5 g/L

· 6 months – 2 years: 0.1 – 0.8 g/L

· 2 – 6 years: 0.2 – 1.5 g/L

· 6 – 12 years: 0.5 – 2.5 g/L

· 12 – 16 years: 0.6 – 3.5 g/L

Note: Adult levels are reached by adolescence. Values are generally slightly higher in males than females.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise total IgA)

· Chronic liver disease – particularly alcoholic cirrhosis and chronic viral hepatitis; IgA is cleared by the liver, and impaired clearance elevates serum IgA.

· Mucosal infections – chronic respiratory, gastrointestinal, or genitourinary infections.

· Autoimmune diseases –

· Rheumatoid arthritis – IgA rheumatoid factor may be elevated.

· IgA vasculitis (Henoch–Schönlein purpura) – acute elevation.

· Dermatitis herpetiformis – strongly associated with IgA deposition and coeliac disease.

· Coeliac disease – IgA anti‑tissue transglutaminase antibodies diagnostic; total IgA often normal or elevated, but may be low in IgA deficiency (which is overrepresented in coeliac disease).

· HIV infection – polyclonal hypergammaglobulinaemia includes IgA.

· IgA monoclonal gammopathy –

· IgA multiple myeloma – IgA paraprotein; associated with osteolytic lesions, renal impairment.

· IgA MGUS – asymptomatic monoclonal spike.

· IgA nephropathy (Berger disease) – glomerular IgA deposition; serum IgA may be elevated in some patients.

b. Indirect correlation (factors that influence IgA independently or falsely)

· Age –

· Infants: physiological IgA deficiency until ~6 months.

· Elderly: modest decline possible.

· Pregnancy – slight physiological decrease.

· Medications –

· Lower IgA: immunosuppressants (corticosteroids, azathioprine, mycophenolate, rituximab, phenytoin, sulfasalazine, gold therapy).

· Raise IgA: interferons, isotretinoin.

· Genetic factors – familial clustering of IgA deficiency; certain HLA haplotypes (HLA‑A1, B8, DR3) strongly associated.

· Assay interference – very high IgA can saturate assay; monoclonal proteins may cause antigen excess (hook effect), requiring dilution.

· Haemodilution / overhydration – spuriously low values.

c. Critical distinction: Selective IgA deficiency vs. normal low IgA

· Selective IgA deficiency – defined as serum IgA <0.07 g/L (or <7 mg/dL) with normal IgG and IgM in individuals ≥4 years. Most common primary immunodeficiency (1:500 in Caucasian populations).

· Partial IgA deficiency – IgA below normal range but detectable (>0.07 g/L); clinical significance less clear, often asymptomatic.

---

4. Disorders related to abnormal values

a. When elevated

Polyclonal (broad increase)

· Chronic liver disease – alcoholic cirrhosis (marked elevation), hepatitis C, non‑alcoholic fatty liver disease.

· Chronic infections – bronchiectasis, chronic osteomyelitis, tuberculosis, HIV.

· Autoimmune / inflammatory diseases – rheumatoid arthritis, Sjögren's syndrome, SLE, IgA vasculitis, psoriasis.

· Coeliac disease – on gluten‑containing diet.

· IgA nephropathy – 30–50% of patients have elevated serum IgA.

Monoclonal (IgA spike on electrophoresis)

· IgA multiple myeloma – second most common myeloma isotype after IgG; often associated with hypercalcaemia, renal failure, anaemia, bone lesions.

· IgA MGUS – monoclonal spike without end‑organ damage; risk of progression to myeloma ~1% per year.

· IgA monoclonal gammopathy of renal significance (MGRS) – monoclonal IgA deposits causing glomerulonephritis without overt myeloma.

b. When low (hypo‑IgA or IgA deficiency)

Primary immunodeficiency

· Selective IgA deficiency – <0.07 g/L; often asymptomatic, but may present with:

· Recurrent sinopulmonary infections (encapsulated bacteria).

· Gastrointestinal infections (Giardia).

· Autoimmune diseases (coeliac disease, ITP, autoimmune thyroiditis, type 1 diabetes).

· Atopic disorders (asthma, allergic rhinitis, eczema).

· Anaphylactic reactions to blood transfusion (due to anti‑IgA antibodies).

· Common variable immunodeficiency (CVID) – low IgG plus low IgA and/or low IgM; recurrent infections, autoimmunity, enteropathy.

· X‑linked agammaglobulinaemia (Bruton) – all immunoglobulins profoundly low; B cells absent.

· Transient hypogammaglobulinaemia of infancy – may involve IgA; resolves spontaneously.

· IgG subclass deficiency – IgA may be normal or low; not diagnostic.

Secondary immunodeficiency

· Immunosuppressive drugs – long‑term corticosteroids, anticonvulsants (phenytoin, carbamazepine), rituximab.

· Protein‑losing states – nephrotic syndrome, protein‑losing enteropathy, severe burns, intestinal lymphangiectasia.

· Chronic lymphocytic leukaemia (CLL) – progressive hypogammaglobulinaemia.

· Multiple myeloma – non‑myeloma immunoglobulins suppressed (immunoparesis).

Physiological / benign

· Partial IgA deficiency (0.07 – 0.7 g/L) – often asymptomatic; may be incidental finding.

Critical safety warning: Patients with selective IgA deficiency (<0.07 g/L) are at risk of severe anaphylactic transfusion reactions due to pre‑formed anti‑IgA antibodies. They must receive IgA‑deficient blood products or washed red cells. This should be clearly documented in medical records and communicated to the patient.

---

5. Best way to address aberrant levels

Important principle: IgA is a diagnostic marker, not a therapeutic target. Treatment is directed at the underlying condition—chronic liver disease, infection, autoimmune disease, myeloma, or immunodeficiency. No intervention exists to raise IgA in selective IgA deficiency. The focus is on managing associated conditions, preventing infections, and avoiding life‑threatening transfusion reactions. Lowering IgA in myeloma requires chemotherapy directed at the plasma cell clone.

a. Quick ways or using Medications

For LOW IgA (selective IgA deficiency, CVID, secondary deficiency)

· Immunoglobulin replacement therapy (IVIG / SCIG) – NOT indicated for isolated IgA deficiency. IVIG contains predominantly IgG and only trace IgA; it does not raise serum IgA.

· Exception: IVIG is indicated for CVID or specific antibody deficiency with recurrent infections, regardless of IgA level. In such patients, low‑IgA or IgA‑depleted IVIG formulations should be used to minimise risk of anaphylaxis in those with anti‑IgA antibodies.

· Treat underlying cause –

· Discontinue offending drug (phenytoin, carbamazepine, sulfasalazine) if safe.

· Manage protein loss (nephrotic syndrome, enteropathy).

· Antibiotic prophylaxis – for recurrent sinopulmonary infections (e.g., amoxicillin, azithromycin).

· Vaccination – ensure pneumococcal, Haemophilus influenzae type b, and influenza vaccines are given; check vaccine responses.

· Screen for associated conditions – coeliac disease (IgG‑based tests; IgA‑tTG is invalid in IgA deficiency), autoimmune thyroiditis, ITP.

· Patient education –

· MedicAlert bracelet indicating IgA deficiency and risk of transfusion reaction.

· Inform all healthcare providers (blood bank, anaesthesia, emergency) before any transfusion.

For HIGH IgA – polyclonal

· Treat underlying disease –

· Alcoholic cirrhosis: abstinence, supportive care; IgA may slowly decline.

· Chronic hepatitis C: direct‑acting antivirals.

· Rheumatoid arthritis: DMARDs.

· IgA nephropathy: optimise blood pressure (ACE inhibitors), consider corticosteroids or immunosuppression in progressive disease.

· Coeliac disease: strict lifelong gluten‑free diet; IgA anti‑tTG normalises over months.

For HIGH IgA – monoclonal (IgA myeloma, IgA MGUS)

· MGUS – no treatment; surveillance.

· IgA multiple myeloma –

· Chemoimmunotherapy – proteasome inhibitors (bortezomib), immunomodulators (lenalidomide), corticosteroids, CD38‑targeting antibodies (daratumumab), autologous stem cell transplantation.

· Supportive care – bisphosphonates for bone health, anaemia management, renal protection.

· Do not self‑prescribe – all require haematology specialist supervision.

· IgA monoclonal gammopathy of renal significance (MGRS) – chemotherapy directed at the clone to preserve renal function.

b. Using Supplements or Holistic medicine

Important: No supplement can raise IgA in selective IgA deficiency. Claims to "boost" IgA are unsubstantiated and potentially dangerous if they delay diagnosis or appropriate management. Adjunctive support for overall immune health is possible but must never replace definitive treatment.

· Vitamin D – deficiency linked to increased infection risk and autoimmunity; supports regulatory T‑cell function.

· Preferred: D3 (cholecalciferol from lichen). Target serum 25‑OH‑D >30 ng/mL.

· Zinc – essential for immune cell development; deficiency impairs mucosal immunity.

· Preferred forms: zinc picolinate, zinc citrate.

· Dose: 15–30 mg elemental zinc daily; avoid chronic high doses.

· Vitamin A – critical for mucosal integrity and IgA production in animal models; human data limited.

· Sources: Beta‑carotene from sweet potato, carrots, spinach, kale; supplementation only if deficiency confirmed.

· Caution: Excess vitamin A (retinol) is hepatotoxic and teratogenic.

· Probiotics – certain strains (Lactobacillus rhamnosus GG, Bifidobacterium lactis) may enhance mucosal IgA secretion in gut, but do not raise serum IgA.

· Sources: Fermented plant foods (kimchi, sauerkraut, kombucha, water kefir, tempeh, miso).

· Note: In patients with CVID or IgA deficiency, some probiotics may cause invasive infection in the setting of immunodeficiency; consult physician before use.

· Beta‑glucans – from fungi (shiitake, maitake, reishi) or yeast; immunomodulatory, may enhance mucosal immunity in animal studies.

· Whole fungi are preferred; extracts available but evidence for IgA deficiency is absent.

· Colostrum (bovine) – contains IgA; sometimes marketed for immune support.

· NOT recommended: Animal‑derived; ecological concerns; no evidence it raises serum IgA in deficient individuals. Avoid.

· Ayurvedic approaches –

· Amalaki (Emblica officinalis) – rich in vitamin C; antioxidant.

· Guduchi (Tinospora cordifolia) – immunomodulatory; limited evidence.

· Ashwagandha (Withania somnifera) – adaptogen.

· Caution: Herbal immunostimulants are contraindicated in patients with autoimmune disease or on immunosuppressants unless explicitly approved by a physician.

· Critical caution:

· Avoid synthetic folic acid and cyanocobalamin in any supplement blend. If B vitamins are required, choose methylfolate and methylcobalamin.

· Echinacea – often promoted for immunity; avoid in autoimmune disease and immunodeficiency; not proven to raise IgA.

· No supplement corrects selective IgA deficiency.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

· General immune‑supportive dietary pattern –

· Whole‑food, plant‑based (WFPB) or Mediterranean‑style plant‑forward diet – abundant in vegetables, fruits, legumes, whole grains, nuts, seeds.

· Adequate protein – essential for antibody synthesis, including secretory IgA at mucosal surfaces.

· Legumes (lentils, chickpeas, beans, tofu, tempeh) – primary protein base.

· Mycoprotein (Quorn) – sustainable fermentation product.

· Edible fungi – shiitake, maitake, oyster, reishi.

· Nuts and seeds – hemp seeds, pumpkin seeds, almonds, walnuts.

· Dairy/eggs – permitted but not emphasised; ecological footprint; precision‑fermented dairy proteins are emerging.

· Meat, poultry, fish – deliberately omitted. Adequate protein for mucosal immunity is readily achievable from plant‑based sources.

· Micronutrients critical for mucosal immunity –

· Zinc – pumpkin seeds, hemp seeds, chickpeas, lentils, cashews.

· Vitamin A / beta‑carotene – sweet potato, carrots, spinach, kale, butternut squash.

· Vitamin C – amla, citrus, kiwi, bell peppers, broccoli, berries.

· Selenium – Brazil nuts (one nut daily).

· Iron – lentils, chickpeas, tofu, spinach (pair with vitamin C).

· Vitamin B12 – only reliable plant‑based source is fortified foods or supplements. Use methylcobalamin.

· Gut‑health and mucosal immunity –

· Dietary fibre – feeds gut microbiota; short‑chain fatty acids (butyrate) support intestinal barrier integrity and IgA secretion.

· Sources: Oats, barley, psyllium, legumes, vegetables, fruits.

· Target: ≥40 g total fibre daily.

· Fermented foods –

· Kimchi, sauerkraut, kombucha, tempeh, miso, water kefir – support microbiome diversity; may enhance secretory IgA in gut (limited human data).

· Specific considerations for IgA disorders –

· Selective IgA deficiency – no specific diet restores serum IgA. Optimal nutrition supports general immune function.

· Coeliac disease screening is mandatory; if diagnosed, strict lifelong gluten‑free diet.

· IgA nephropathy – sodium restriction, blood pressure control; emerging evidence for plant‑based diets in reducing proteinuria and inflammation.

· IgA vasculitis (Henoch–Schönlein purpura) – during acute phase, soft, bland diet if abdominal involvement.

· IgA myeloma – during chemotherapy, plant‑based diets rich in antioxidants and fibre may support gut health and reduce inflammation. Avoid raw foods during profound neutropenia.

· Foods to minimise –

· Ultra‑processed foods, refined sugars, excessive alcohol – impair immune function and gut barrier integrity.

· Industrial seed oils high in omega‑6 – promote pro‑inflammatory eicosanoids.

· Excessive salt – may exacerbate IgA nephropathy.

---

6. How soon can one expect improvement and the ideal time frame to retest

· Coeliac disease – on strict gluten‑free diet, IgA anti‑tTG antibody titres decline over 3–12 months; total IgA remains unchanged (except in IgA deficiency).

· Alcoholic cirrhosis – with sustained abstinence, IgA may decrease slowly over months to years.

· Chronic hepatitis C – after successful antiviral therapy, polyclonal IgA declines over 6–12 months.

· IgA nephropathy – treatment response measured by proteinuria and renal function, not serum IgA.

· IgA multiple myeloma – monoclonal IgA declines slowly; response assessed at end of each treatment cycle (4–8 weeks) ; significant reduction often takes 2–4 months.

· Drug‑related IgA suppression – after discontinuing offending drug (phenytoin, carbamazepine), IgA recovery may take weeks to months.

· Selective IgA deficiency – does not improve with age or intervention. Spontaneous remission is exceptionally rare. Once diagnosed, it is lifelong.

Retesting interval –

· Selective IgA deficiency – confirm with repeat testing; if asymptomatic, no routine repeat needed unless clinical change. Family screening may be offered.

· Partial IgA deficiency (0.07–0.7 g/L) – repeat annually until stable; if remains low but stable and asymptomatic, no further action.

· CVID / hypogammaglobulinaemia – monitor IgG trough (if on IVIG) and infection frequency; IgA itself not routinely rechecked.

· Monoclonal IgA (MGUS) – serum protein electrophoresis with IgA quantitation every 3–6 months initially, then annually if stable.

· IgA multiple myeloma – IgA monitored monthly during active therapy, then every 3–6 months during remission.

· IgA nephropathy – serum IgA not used to monitor disease activity; renal function and proteinuria are the relevant parameters.

---

Conclusion

Immunoglobulin A is the immune system's sentinel at the mucosal frontier. A low IgA level—particularly below 0.07 g/L—defines the most common primary immunodeficiency, affecting 1 in 500 individuals. Most are asymptomatic, but some face recurrent infections, autoimmune diseases, and a life‑threatening risk of anaphylaxis to blood products. There is no cure and no supplement that raises IgA. Management is vigilance: screening for associated conditions, prompt infection treatment, and indelible documentation of transfusion precautions. Elevated IgA points toward chronic liver disease, mucosal inflammation, autoimmune conditions, or a plasma cell dyscrasia requiring haematological evaluation. Ecologically responsible nutrition—legumes over livestock, fungi over fish, fermentation over feedlots—provides ample protein and micronutrients to support mucosal integrity and general immune competence. But it does not replace missing IgA. As with all immunological tests, IgA is interpreted not in isolation but alongside infection history, autoimmune associations, and the singular precaution that can save a life: the knowledge of deficiency before transfusion.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x